The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from an early phase trial of in situ immunization of lymphoma with a virus likeparticle containing a TLR9 agonist combined with anti-PD1 therapy (NCT03983668).
 
Umar Farooq
Honoraria - Kite, a Gilead company; Morphosys
Research Funding - Checkmate Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Sabarish Ram Ayyappan
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Fate Therapeutics; Intellisphere; Seagen; TG Therapeutics
Research Funding - beigene (Inst); Genmab (Inst); Regeneron (Inst)
 
Chaobo Yin
No Relationships to Disclose
 
Caitlin Lemke-Miltner
No Relationships to Disclose
 
Brian J. Smith
No Relationships to Disclose
 
Brian K. Link
Consulting or Advisory Role - Genentech/Roche; MEI Pharma
Research Funding - Genentech/Abbvie (Inst); Pharmacyclics/Janssen (Inst)
 
George J. Weiner
Leadership - LIRECAP
Stock and Other Ownership Interests - LIRECAP
Consulting or Advisory Role - Regeneron
Research Funding - Checkmate Pharmaceuticals; Pfizer